睿知中国医院研究地图
候选清单

泸州西南医科大学

西南医科大学附属医院

Affiliated Hospital of Southwest Medical University

在本站收录的 53 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

西南医科大学附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma15 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma97 篇牵头论文
  4. 胃癌Stomach cancer39 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma1 篇牵头论文
  7. 骨肉瘤Osteosarcoma20 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma3 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  12. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  13. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  14. β 地中海贫血Beta thalassaemia3 篇牵头论文
  15. 范可尼贫血Fanconi anaemia1 篇牵头论文
  16. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis3 篇牵头论文
  17. 大动脉炎Takayasu arteritis1 篇牵头论文
  18. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  20. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  21. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  22. 白塞病Behçet disease1 篇牵头论文
  23. Alport 综合征Alport syndrome1 篇牵头论文
  24. IgA 肾病IgA nephropathy3 篇牵头论文
  25. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  26. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  27. 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.6%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 4420232024: 3320242025: 332025

泸州有 1 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能诱导/同步化疗放疗技术
论文中的科室耳鼻喉/头颈外科肿瘤内科影像/核医学科
牵头的论文15
  1. Serum HOTTIP expression is upregulated in nasopharyngeal carcinoma patients and predicts poor prognosis.2025Brazilian journal of otorhinolaryngology免费全文
  2. Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment.2025Clinical and experimental medicine免费全文
  3. Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT for tumor staging and primary tumor volume delineation in patients with nasopharyngeal carcinoma.2025Scientific reports免费全文
  4. Development of a neoadjuvant chemotherapy efficacy prediction model for nasopharyngeal carcinoma integrating magnetic resonance radiomics and pathomics: a multi-center retrospective study.2024BMC cancer免费全文
  5. Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma.2024Molecular imaging and biology
  6. Comprehensive analysis revealed P4Hs as new biomarkers for prognosis and immunotherapy in head and neck cancer.2024Scientific reports免费全文
  7. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy.2023BMC cancer免费全文
  8. Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial.2023International journal of radiation oncology, biology, physicsRCT
  9. Long non-coding RNA HOTTIP exerts an oncogenic function by regulating HOXA13 in nasopharyngeal carcinoma.2023Molecular biology reports免费全文
  10. HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-2.2023Scientific reports免费全文
  11. Development of a Radiotherapy Localisation Computed Tomography-Based Radiomic Model for Predicting Survival in Patients With Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy Following Induction Chemotherapy.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  12. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.2022Scientific reports免费全文
  13. Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis.2022Systematic reviews免费全文
  14. Minimally Invasive Surgery for Early-Stage Nasopharyngeal Carcinoma.2022The Journal of craniofacial surgery免费全文
  15. FANCD2 knockdown with shRNA interference enhances the ionizing radiation sensitivity of nasopharyngeal carcinoma CNE-2 cells.2021Neoplasma
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC状态不明NCT04830267研究中心II期2021-03 启动
  2. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  3. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma状态不明NCT02211677研究中心2014-08 启动
PubMed 以外找到的论文(未计入)9
  1. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  2. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computing论文
  3. Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  4. The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma2025International Journal of Radiation Research论文
  5. HOXA13 promotes the proliferation, migration, and invasion of nasopharyngeal carcinoma HNE1 cells by upregulating the expression of Snail and MMP-22022Laryngo-Rhino-Otologie论文
  6. Interim Results of a Prospective, Randomized, Multicenter, Phase 3 Study of the Efficacy of Increasing the Cycles of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physics论文
  7. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figshare数据集
  8. Correlation Between Immune Function Status and EBV DNA in Patients with Nasopharyngeal Carcinoma and Their Influence on Prognosis2021DOAJ (DOAJ: Directory of Open Access Journals)论文
  9. EBV-positive LMP1-mediated Signal Pathway in Nasopharyngeal Carcinoma2021Learning & Education论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 6620232024: 2220242025: 222025

泸州有 1 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜分子标志物与基因放疗
论文中的科室消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. SND1-SMARCA5 interaction strengthened by PIM promotes the proliferation, metastasis, and chemoresistance of esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  2. Esophageal cancer and precancerous lesions: focus on resident bacteria and fungi.2025Microbiology spectrum免费全文
  3. Non-endoscopic Screening for Esophageal Squamous Cell Carcinoma: Recent Advances.2024Journal of gastrointestinal cancer
  4. ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma.2024Medical oncology (Northwood, London, England)免费全文
  5. Expression of Polyadenylate-binding Protein Cytoplasmic 1 (PABPC1) in Combination With RAD51 as Prognostic Biomarker in Patients Who Underwent Postoperative Chemotherapy for Esophageal Squamous Cell Carcinoma.2023Applied immunohistochemistry & molecular morphology : AIMM
  6. Metastasis to recurrent laryngeal nerve lymph nodes as a predictor of cervical lymph node metastasis in esophageal squamous cell carcinoma.2023Asian journal of surgery
  7. Engrailed 2 triggers the activation of multiple phosphorylation-induced signaling pathways in both transcription-dependent and -independent manners.2023Biochemical and biophysical research communications
  8. Hypoxia-responsive lncRNA G077640 promotes ESCC tumorigenesis via the H2AX-HIF1α-glycolysis axis.2023Carcinogenesis
  9. Circ_0024108 promotes the progression of esophageal cancer cells.2023General thoracic and cardiovascular surgery
  10. Erianin Exerts Antineoplastic Effects on Esophageal Squamous Cell Carcinoma Cells by Activating the cGMP-PKG Signaling Pathway.2023Nutrition and cancer
  11. KDM2A plays a dual role in regulating the expression of malignancy-related genes in esophageal squamous cell carcinoma.2022Biochemical and biophysical research communications
  12. CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis.2022Bioengineered免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)12
  1. 253. MICROBIOTA ENTEROTOXIGENIC BACTEROIDES FRAGILIS (ETBF) PROMOTES ESCC TUMOR FORMATION, MIGRATION, AND INVASION BY PROMOTING EMT AND ACTIVATING TLR4/NF-κB SIGNALING PATHWAY2025Diseases of the Esophagus论文
  2. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  3. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  4. Long-term survival of esophageal squamous cell carcinoma after surgical treatment in a large-scale retrospective study from a single cancer center2023Holistic Integrative Oncology论文
  5. Overexpression of CXCL5 promotes proliferation and infiltration of esophageal squamous cell carcinoma2023Research Square预印本
  6. 629 IRRADIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELLS INDUCED THE INCREASE OF TREG BY TGF-β2021Diseases of the Esophagus论文
  7. 631 CLINICAL APPLICATION VALUE OF THE SYSTEMIC-IMMUNE-INFLAMMATION-INDEX FOR PREDICTING SURVIVAL IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA UNDERGOING CHEMORADIOTHERAPY OR RADIOTHERAPY2021Diseases of the Esophagus论文
  8. 685 THE IMPACT OF ADJUVANT THERAPY ON SURVIVAL FOR NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PROPENSITY SCORE MATCHED ANALYSIS2021Diseases of the Esophagus论文
  9. 695 METASTASIS OF THORACIC RECURRENT LARYNGEAL NERVE LYMPH NODE AS PREDICTOR FOR CERVICAL LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagus论文
  10. KDM6B Promotes ESCC Cell Proliferation and Metastasis by Facilitating C/EBPβ Transcription2021Research Square预印本
  11. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figshare数据集
  12. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 97 篇,占 0.7%。

牵头论文
97
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 242420222023: 252520232024: 202020242025: 19192025

泸州有 1 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  2. 正在招募
    GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
    分期
    不分期
    开始
    2021-09
    登记号
    NCT05047510

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心泸州、珠海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室肿瘤内科普外/肝胆胰外科病理/检验科影像/核医学科
牵头的论文97
  1. Synthesis and antitumor evaluation of glycyrrhetinic acid-dithiocarbamate hybrids.2025Archiv der Pharmazie
  2. Prediction model establishment of prognosis factors for distant metastasis of hepatocellular carcinoma based on the SEER database.2025Cancer epidemiology
  3. WWP2-induced inhibition of hepatocellular carcinoma cellular senescence via the ubiquitination and degradation of p21.2025Cell death & disease免费全文
  4. Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Icaritin-Loaded Liposomes Mediated by Hyaluronic Acid Promoted the Anti-Proliferation and Senescence in Huh7 Cells.2025Drug development research
  6. ANG secretion predisposes endothelial cells toward angiogenesis in FIN56-induced ferroptotic hepatocellular carcinoma via the BMP6/ID1 signaling pathway.2025Free radical biology & medicine
  7. ARIH2 serves as a potential prognostic biomarker for hepatocellular carcinoma associated with immune infiltration and ferroptosis.2025Frontiers in immunology免费全文
  8. Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  9. Machine Learning-Based Integration of Single-Cell and Bulk Transcriptome Reveals Coagulation Signature and Phenotypic Heterogeneity in Hepatocellular Carcinoma.2025IET systems biology免费全文
  10. Risk factors and clinical outcomes in patients with HCV eradication by direct-acting antivirals: a systematic review and meta-analysis.2025Infectious diseases (London, England)
  11. The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma.2025International journal of nanomedicine免费全文
  12. Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study.2025Investigational new drugs免费全文
  13. Letter to the editor comments on 'PBK as a Novel Biomarker with Excellent Diagnostic and Prognostic Value in HCC Associated with Immune Infiltration and Methylation'.2025Journal of molecular histology免费全文
  14. HDAC2-mediated chromatin remodeling drives hepatocellular carcinoma progression: an integrative analysis of computational pathology and multi-transcriptomics.2025Journal of translational medicine免费全文
  15. ANXA2 in hepatocellular carcinoma: orchestrating tumorigenesis, progression, and therapeutic resistance toward precision targeting.2025Journal of translational medicine免费全文
  16. Asiaticoside enhances the anti-tumor effect of anti-PDL1 by regulating T cell activity through increasing LCK activity.2025Pathology, research and practice
  17. Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  18. Asparagine synthetase modulates glutaminase inhibitor sensitivity through metabolic reprogramming and serves as a prognostic biomarker in hepatocellular carcinoma.2025Redox biology免费全文
  19. Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.2025The American journal of case reports免费全文
  20. PART1 facilitates tumorigenesis and inhibits ferroptosis by regulating the miR-490-3p/SLC7A11 axis in hepatocellular carcinoma.2024Aging免费全文
  21. GLO1 regulates hepatocellular carcinoma proliferation and migration through the cell cycle pathway.2024BMC cancer免费全文
  22. CT radiomics based on different machine learning models for classifying gross tumor volume and normal liver tissue in hepatocellular carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  23. Integration of single-cell and bulk RNA-sequencing to analyze the heterogeneity of hepatocellular carcinoma and establish a prognostic model.2024Cancer reports (Hoboken, N.J.)免费全文
  24. Identification of formononetin as the active compound of CR-SR in hepatocellular carcinoma treatment: An integrated approach combining network pharmacology and weighted gene co-expression networks.2024Chemical biology & drug design
  25. Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy.2024Colloids and surfaces. B, Biointerfaces
  26. Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.2024European journal of medical research免费全文
  27. PRMT1-mediated arginine methylation promotes YAP activation and hepatocellular carcinoma proliferation.2024FEBS open bio免费全文
  28. Role and therapeutic potential of E3s in the tumor microenvironment of hepatocellular carcinoma.2024Frontiers in immunology免费全文
  29. Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance.2024Frontiers in immunology免费全文
  30. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.2024Frontiers in immunology免费全文
  31. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.2024Immunology
  32. A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy.2024International journal of nanomedicine免费全文
  33. Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.2024Journal of cancer research and clinical oncology免费全文
  34. Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.2024Journal of gastroenterology and hepatology
  35. Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway.2024Molecular cancer免费全文
  36. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.2024Scientific reports免费全文
  37. FXR, MRP-1 and SLC7A5: New Targets for the Treatment of Hepatocellular Carcinoma.2024Technology in cancer research & treatment免费全文
  38. Obesity phenotype induced by high-fat diet promotes diethylnitrosamine (DEN)-induced precancerous lesions by M1 macrophage polarization in mice liver.2024The Journal of nutritional biochemistry
  39. Potential applications of dual haptoglobin expression in the reclassification and treatment of hepatocellular carcinoma.2024Translational research : the journal of laboratory and clinical medicine
  40. Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy.2023ACS applied materials & interfaces
  41. TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer.2023Aging免费全文
  42. Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study.2023Annals of hepatologyRCT
  43. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.2023BMC gastroenterology免费全文
  44. A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification.2023BMC gastroenterology免费全文
  45. Chemical profiling and investigation of molecular mechanisms underlying anti-hepatocellular carcinoma activity of extracts from Polygonum perfoliatum L.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  46. Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning.2023Briefings in bioinformatics免费全文
  47. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  48. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.2023Clinical and experimental medicine免费全文
  49. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.2023Clinical and experimental medicine免费全文
  50. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.2023European journal of medical research免费全文
  51. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.2023European journal of pharmacology
  52. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period.2023Frontiers in immunology免费全文
  53. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.2023Frontiers in immunology免费全文
  54. Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo.2023International journal of nanomedicine免费全文
  55. Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals.2023International journal of oncology免费全文
  56. A commentary on 'Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies' [Int J Surg 105 (2022) 106821].2023International journal of surgery (London, England)免费全文
  57. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.2023Journal of nanobiotechnology免费全文
  58. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.2023Oncology research免费全文
  59. Deciphering the tumour immune microenvironment of hepatocellular carcinoma.2023Scandinavian journal of immunology
  60. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma.2023Scientific reports免费全文
  61. A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma.2023Scientific reports免费全文
  62. α-LA attenuates microcystin-LR-induced hepatocellular oxidative stress in mice through Nrf2-mediated antioxidant and detoxifying enzymes.2023Toxicon : official journal of the International Society on Toxinology
  63. Construction of a diagnostic model for hepatitis B-related hepatocellular carcinoma using machine learning and artificial neural networks and revealing the correlation by immunoassay.2023Tumour virus research免费全文
  64. Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?2023Updates in surgery免费全文
  65. THRSP identified as a potential hepatocellular carcinoma marker by integrated bioinformatics analysis and experimental validation.2022Aging免费全文
  66. Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.2022Annals of hepatology
  67. CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.2022Bioengineered免费全文
  68. Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma.2022Cells免费全文
  69. LRFNet: A deep learning model for the assessment of liver reserve function based on Child-Pugh score and CT image.2022Computer methods and programs in biomedicine
  70. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma.2022Computers in biology and medicine
  71. Roles of M6A Regulators in Hepatocellular Carcinoma: Promotion or Suppression.2022Current gene therapy
  72. Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma.2022Current oncology (Toronto, Ont.)免费全文
  73. Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma.2022Drug delivery免费全文
  74. Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  75. Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway.2022Frontiers in immunology免费全文
  76. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.2022Frontiers in immunology免费全文
  77. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study.2022Hepatology international免费全文
  78. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.2022Hepatology international免费全文
  79. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma.2022Hepatology international
  80. The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.2022Investigational new drugs
  81. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma.2022Journal of biochemical and molecular toxicology
  82. Development of a Hepatic VX2 carcinoma model in rabbits using an improved minimally invasive method and evaluation with imaging examinations.2022Journal of cancer research and therapeutics
  83. LncRNA NCK1-AS1 Aggravates Hepatocellular Carcinoma by the miR-22-3p/YARS Axis to Activate PI3K/AKT Signaling.2022Journal of gastrointestinal and liver diseases : JGLD
  84. Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.2022Molecules (Basel, Switzerland)免费全文
  85. Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images.2022Oncology research免费全文
  86. Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.2022Phytotherapy research : PTR
  87. The relationship between NTCP gene varieties and the progress of liver disease after HBV infection: an updated systematic review and meta-analysis.2022The American journal of the medical sciences
  88. The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.2022The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  89. Inflow vascular occlusion technique versus hemihepatic vascular maneuver in hepatectomy: A systematic review and meta-analysis.2021Asian journal of surgery
  90. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.2021BMC cancer免费全文
  91. miR-381 Reverses Multidrug Resistance by Negative Regulation of the CTNNB1/ABCB1 Pathway in HepG2/Dox Cells, and the Diagnostic and Prognostic Values of CTNNB1/ABCB1 Are Identified in Patients with LIHC.2021DNA and cell biology
  92. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  93. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis.2021International journal of biological sciences免费全文
  94. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.2021International journal of nanomedicine免费全文
  95. FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  96. Early versus Delayed Hepatectomy for Spontaneously Ruptured Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  97. Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis.2021Pathology, research and practice
中文论文(未计入)2
  1. [Silencing SIRT1 reduces 5-fluorouracil resistance of cholangiocarcinoma cells by inhibiting the FOXO1/Rab7 autophagy pathway].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [MicroRNA 424-5p promotes the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting Kinesin family member 23].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  2. GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma正在招募NCT05047510研究中心不分期2021-09 启动
  3. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  4. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 39 篇,占 0.4%。

牵头论文
39
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 5520222023: 111120232024: 121220242025: 332025

泸州有 1 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题免疫与靶向药物影像与人工智能早期发现与内镜
论文中的科室消化/肝病科普外/肝胆胰外科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文39
  1. The impact of multidimensional interactions among Helicobacter pylori infection, tumor microenvironment, and gut microbiota on gastric cancer immune response.2026European journal of pharmacology
  2. Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application.2025Frontiers in immunology免费全文
  3. Glucose metabolism reprogramming in gastric cancer: Implications for tumor.2025International immunopharmacology
  4. Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer.2025Neoplasia (New York, N.Y.)免费全文
  5. Identification of immunotherapy-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognostic signature in gastric carcinoma.2024Aging免费全文
  6. Downregulation of PDIA3 inhibits gastric cancer cell growth through cell cycle regulation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Deep learning is necessary for safety regulation in predicting malnutrition in gastric cancer patients.2024Clinical nutrition (Edinburgh, Scotland)
  8. eIF6 Promotes Gastric Cancer Proliferation and Invasion by Regulating Cell Cycle.2024Digestive diseases and sciences免费全文
  9. Dysregulation of systemic immunity and its clinical application in gastric cancer.2024Frontiers in immunology免费全文
  10. Letter to the Editor for the article 'A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study'.2024International journal of surgery (London, England)免费全文
  11. Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression.2024Journal of advanced research免费全文
  12. Cause of death among gastric cancer survivors in the United States from 2000 to 2020.2024Medicine免费全文
  13. LncRNA RP11-93B14.5 promotes gastric cancer cell growth through PI3K/AKT signaling pathway.2024Molecular biotechnology
  14. Circadian rhythm genes contribute to the prognosis prediction and potential therapeutic target in gastric cancer.2024Scientific reports免费全文
  15. Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing.2024Scientific reports免费全文
  16. Supradiaphragmatic Gastric Monodermal Teratoma With Bronchus-Like Structures.2024The American journal of gastroenterology
  17. Pulling out the radish without mud: Endoscopic blunt dissection of a gastric submucosal tumor.2023Asian journal of surgery
  18. The effect of liver transplantation on gastric cancer: A meta-analysis.2023Asian journal of surgery
  19. Gastric cancer incidence trends in China and Japan from 1990 to 2019: Disentangling age-period-cohort patterns.2023Cancer
  20. miR-199a-3p promotes gastric cancer progression by promoting its stemness potential via DDR2 mediation.2023Cellular signalling
  21. Giant gastric myxoid epithelioid gastrointestinal stromal tumor.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  22. Dual-Regulated Mechanism of EZH2 and KDM6A on SALL4 Modulates Tumor Progression via Wnt/β-Catenin Pathway in Gastric Cancer.2023Digestive diseases and sciences
  23. Cd44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor.2023Expert review of molecular diagnostics
  24. SDPR Inhibits TGF-β Induced Cancer Metastasis Through Fatty Acid Oxidation Regulation in Gastric Cancer.2023International journal of biological sciences免费全文
  25. Endoscopic Removal of an Embedded Fishbone in the Gastric Antrum.2023Journal of gastrointestinal and liver diseases : JGLD
  26. Gender authorship trends of gastric cancer in the top journals of gastroenterology: A 20-year perspective.2023Medicine免费全文
  27. Association between blood lipid levels and risk of gastric cancer: A systematic review and meta-analysis.2023PloS one免费全文
  28. FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  29. Reverse rolling-mat type lymph node dissection is the key step to solve the operative difficulties in hand-assisted laparoscopic D2 radical gastrectomy.2022BMC surgery免费全文
  30. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA.2022BMJ open免费全文
  31. The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer.2022Current medicinal chemistry
  32. H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.2022World journal of surgical oncology免费全文
  33. Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer.2021BioMed research international免费全文
  34. Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer.2021Bioscience reports免费全文
  35. Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer.2021Clinical and translational medicine免费全文
  36. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.2021Clinical immunology (Orlando, Fla.)
  37. The Multifaceted Role of Long Non-Coding RNA in Gastric Cancer: Current Status and Future Perspectives.2021International journal of biological sciences免费全文
  38. Vitamin D suppressed gastric cancer cell growth through downregulating CD44 expression in vitro and in vivo.2021Nutrition (Burbank, Los Angeles County, Calif.)
  39. The distinct roles of exosomes in tumor-stroma crosstalk within gastric tumor microenvironment.2021Pharmacological research
中文论文(未计入)1
  1. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

泸州有 1 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文1
  1. Detection of Parotid Metastasis from Retinoblastoma by 18F-FDG PET/CT scan.2022Revista espanola de medicina nuclear e imagen molecular

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

泸州有 1 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.9%。

牵头论文
20
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 3320232024: 6620242025: 662025

泸州有 2 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科儿科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文20
  1. KC1036 in ewing sarcoma: mechanistic insights and future directions for a multi-targeted therapeutic strategy.2025Angiogenesis
  2. Incidence trends, overall survival, and metastasis prediction using multiple machine learning and deep learning techniques in pediatric and adolescent population with osteosarcoma and Ewing's sarcoma: nomogram and webpage.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Challenges in Diagnosing Primary Intracranial Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report.2025Current medical imaging
  4. KIAA1429 as a therapeutic target in osteosarcoma: challenging the linear ferroptosis pathway and evaluating translational hurdles.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  5. Plasma proteins and osteosarcoma: Mendelian randomization analysis and targeted therapeutic discovery.2025Medicine
  6. Primary Pulmonary Osteosarcoma Presenting as a 1.7-cm Subpleural Nodule in a 61-Year-Old Man: A Case Report.2025The American journal of case reports免费全文
  7. Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies.2024Cancer biology & medicine
  8. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.2024Chemico-biological interactions
  9. Investigating the molecular mechanism of Mori Cortex against osteosarcoma by bioinformatics analysis and in vitro experimental.2024Medicine
  10. Honokiol inhibits human osteosarcoma MG63 cell migration by upregulating FTO and Smad6 to promote autophagy.2024Molecular and cellular probes
  11. Circular RNA IARS modulates the progression and ferroptosis of osteosarcoma via sponging miR-188-5p from RAB14.2024Neoplasma
  12. Tumor-derived microparticles promoted M2-like macrophages polarization to stimulate osteosarcoma progression.2024The international journal of biochemistry & cell biology
  13. The Long Noncoding RNA ZEB2-AS1 Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma.2023Cancer biotherapy & radiopharmaceuticals
  14. ITGB3 promotes cisplatin resistance in osteosarcoma tumors.2023Cancer medicine
  15. Identification of genes contributing to cisplatin resistance in osteosarcoma cells.2023FEBS open bio
  16. Hox transcript antisense RNA knockdown inhibits osteosarcoma progression by regulating the phosphoinositide 3-kinase/AKT pathway through the microRNA miR-6888-3p/spleen tyrosine kinase axis.2022Bioengineered
  17. TGF-β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1α dependent manner.2021BMC cancer
  18. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9).2021Bioengineered
  19. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma.2021Cell biology international
  20. Limb-salvage surgery using personalized 3D-printed porous tantalum prosthesis for distal radial osteosarcoma: A case report.2021Medicine
早期论文(2016–2020 年)6
  1. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.2019Gene
  2. Screening candidate microRNA-mRNA network for predicting the response to chemoresistance in osteosarcoma by bioinformatics analysis.2019Journal of cellular biochemistry
  3. The relationship between the expression of TAM, survivin and the degree of necrosis of the tumor after cisplatin treatment in osteosarcoma.2017European review for medical and pharmacological sciences
  4. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.2017IUBMB life
  5. The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma.2017Minerva medica
  6. The metastasis suppressor gene KISS-1 regulates osteosarcoma apoptosis and autophagy processes.2017Molecular medicine reports

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科影像/核医学科
牵头的论文1
  1. Giant gastric myxoid epithelioid gastrointestinal stromal tumor.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
中文论文(未计入)1
  1. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
早期论文(2016–2020 年)1
  1. Traction with snare during endoscopic submucosal dissection of a gastrointestinal stromal tumor in the gastric fundus.2016Endoscopy

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

泸州有 1 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

泸州有 1 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 4420232024: 1120242025: 112025

泸州有 1 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药肾脏与骨骼并发症
论文中的科室肾内科影像/核医学科
牵头的论文10
  1. Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.2025Clinical and experimental medicine免费全文
  2. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.2024Expert review of hematology
  3. 18F‑FDG PET/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma.2023BMC medical imaging免费全文
  4. Repurposing Metformin in hematologic tumor: State of art.2023Current problems in cancer
  5. Non-crystalline light chain proximal tubular disease associated with Waldenström macroglobulinemia.2023International urology and nephrology
  6. LAMP5 may promote MM progression by activating p38.2023Pathology oncology research : POR免费全文
  7. Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.2022BMC cancer免费全文
  8. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.2022European journal of nuclear medicine and molecular imaging
  9. The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.2022European review for medical and pharmacological sciences
  10. Serum metabolomics reveals the effects of accompanying treatment on fatigue in patients with multiple myeloma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

泸州有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
研究主题干细胞移植费城染色体与遗传学
论文中的科室儿科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

泸州有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
论文中的科室神经外科儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

泸州有 1 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

泸州有 1 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

泸州有 1 家医院列在肝包虫病下全国有 44 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

泸州有 1 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文1
  1. Incidental lymphangioleiomyomatosis in pelvic lymph nodes associated with Malignant neoplasm of the ovary - two case reports.2023Polish journal of pathology : official journal of the Polish Society of Pathologists

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

泸州有 1 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

泸州有 1 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

泸州有 2 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

泸州有 1 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

泸州有 1 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

泸州有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

西南医科大学附属医院

Affiliated Hospital of Southwest Medical University

泸州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Southwest Medical University; Affiliated Hospital of South West Medical University; Affliated Hospital of Southwest Medical University; First Affiliated Hospital of Southwest Medical University; Affiliated Hospital of SouthWest Medical University; Hospital (T.C.M) Affiliated to Southwest Medical University; Affiliated to Southwest Medical University; Affiliated TCM Hospital of Southwest Medical University

提出更正下载数据